Opposing Roles for Cannabinoid Receptor Type-I (CB₁) and Transient Receptor Potential Vanilloid Type-I Channel (TRPV1) on the Modulation of Panic-Like Responses in Rats

Plínio C Casarotto¹, Ana Luisa B Terzian^{2,3}, Daniele C Aguiar⁴, Hélio Zangrossi¹, Francisco S Guimarães¹, Carsten T Wotjak² and Fabrício A Moreira^{*,4}

¹Department of Pharmacology, School of Medicine of Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil; ²Max Planck Institut für Psychiatrie, Research Group Neuronal Plasticity, Munich, Germany; ³Graduate School of Neuroscience, Ludwig Maximilians Universität, Munich, Germany; ⁴Department of Pharmacology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil

The midbrain dorsal periaqueductal gray (dPAG) has an important role in orchestrating anxiety- and panic-related responses. Given the cellular and behavioral evidence suggesting opposite functions for cannabinoid type I receptor (CB₁) and transient receptor potential vanilloid type-I channel (TRPV1), we hypothesized that they could differentially influence panic-like reactions induced by electrical stimulation of the dPAG. Drugs were injected locally and the expression of CB₁ and TRPV1 in this structure was assessed by immunofluorescence and confocal microscopy. The CB₁-selective agonist, ACEA (0.01, 0.05 and 0.5 pmol) increased the threshold for the induction of panic-like responses solely at the intermediary dose, an effect prevented by the CB₁-selective antagonist, AM251 (75 pmol). Panicolytic-like effects of ACEA at the higher dose were unmasked by pre-treatment with the TRPV1 antagonist capsazepine (0.1 nmol). Similarly to ACEA, capsazepine (1 and 10 nmol) raised the threshold for triggering panic-like reactions, an effect mimicked by another TRPV1 antagonist, SB366791 (1 nmol). Remarkably, the effects of both capsazepine and SB366791 were prevented by AM251 (75 pmol). These pharmacological data suggest that a common endogenous agonist may have opposite functions at a given synapse. Supporting this view, we observed that several neurons in the dPAG co-expressed CB₁ and TRPV1. Thus, the present work provides evidence that an endogenous substance, possibly anandamide, may exert both panicolytic and panicogenic effects via its actions at CB₁ receptors and TRPV1 channels, respectively. This tripartite set-point system might be exploited for the pharmacotherapy of panic attacks and anxiety-related disorders.

Neuropsychopharmacology (2012) **37**, 478–486; doi:10.1038/npp.2011.207; published online 21 September 2011

Keywords: panic; anxiety; periaqueductal gray; cannabinoid; vanilloid; anandamide

INTRODUCTION

Panic disorder is a subtype of anxiety spectrum disorders characterized by recurrent episodes of panic attacks, which comprise intense feelings of fear and distress, accompanied by tachycardia, hyperventilation and increased blood pressure (Katon, 2006; Roy-Byrne *et al*, 2006). Although its precise neural basis has remained uncertain, evidence indicates that it might result from a malfunction in brain systems related to defense reactions (McNaughton and Gray, 2000). Accordingly, panic attacks exhibit isomorphism with flight responses regarding their autonomic,

behavioral and psychological aspects (Bandler *et al*, 2000; McNaughton and Gray, 2000).

Among the brain regions that may participate in the elaboration of both panic and innate defense reactions is the midbrain dorsal periaqueductal gray (dPAG), comprising dorsomedial and dorsolateral columns (Del-Ben and Graeff, 2009; Schenberg *et al*, 2001). In humans, electrical stimulation of this structure induces an intensive feeling of aversion, fear and imminent death along with autonomic changes (Nashold *et al*, 1969). Moreover, neuroimaging studies detected increased activity in this region in patients suffering from panic (Del-Ben and Graeff, 2009) and in healthy volunteers exposed to a proximal threatening stimulus (Mobbs *et al*, 2007). In laboratory rats, local electrical or chemical dPAG stimulation induces autonomic changes along with escape responses (Beckett and Marsden, 1995; Krieger and Graeff, 1985; Schenberg *et al*, 2001). In addition, systemic or intradPAG injections of panicolytic drugs increase the threshold required to induce escape responses (Hogg *et al*, 2006; Jenck *et al*, 1995; Schenberg

*Correspondence: Dr FA Moreira, Department of Pharmacology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Av. Antonio Carlos, 6627 Belo Horizonte, MG 31270-901, Brazil, Tel: +55 31 3409 2720, Fax: +55 31 3409 2645, E-mail: fabriciomoreira@icb.ufmg.br

Received 5 July 2011; revised 5 August 2011; accepted 10 August 2011

et al, 2001; Schütz *et al*, 1985). Due to its robust face, construct and predictive validity, the escape reaction resulting from electrical stimulation of the rat dPAG has been proposed as a model of panic attacks (Beckett and Marsden, 1995; Del-Ben and Graeff, 2009; Jenck *et al*, 1995; Schenberg *et al*, 2001).

Diverse types of receptors are expressed in the PAG, including the G-protein coupled cannabinoid type 1 receptor (CB₁) and the transient receptor potential type-1 (TRPV1) channel (Cavanaugh *et al*, 2011; Cristino *et al*, 2006; Herkenham *et al*, 1990, 1991; Mezey *et al*, 2000; Tóth *et al*, 2005; Tsou *et al*, 1998). These receptors may bind common endogenous ligands, which are thus termed endocannabinoids/endovanilloids, such as arachidonoyl ethanolamide (anandamide) (for reviews, see Di Marzo, 2008; Di Marzo *et al*, 2001 and Starowicz *et al*, 2007a). Despite this similarity, electrophysiological and neurochemical pieces of evidence indicate that they may have opposite functions. In the PAG, local CB₁ activation inhibits calcium channels and excitatory neuronal activity (Vaughan *et al*, 2000), whereas TRPV1 promotes calcium influx and glutamate release (Starowicz *et al*, 2007b; Xing and Li, 2007). At the behavioral level, CB₁ knockout mice show deficits in extinction and habituation of conditioned fear (Kamprath *et al*, 2006; Marsicano *et al*, 2002) and exacerbated anxiety-like behavior (Haller *et al*, 2002, 2004; Jacob *et al*, 2009; Martin *et al*, 2002). On the contrary, TRPV1 knockout mice show reduced fear- and anxiety-like responses (Marsch *et al*, 2007). Finally, either local activation of CB₁ or blockade of TRPV1 at level of the dorsolateral columns of the PAG-induced anxiolytic-like effects (Lisboa *et al*, 2008; Moreira *et al*, 2007, 2009; Terzian *et al*, 2009). The same is observed with either systemic or intraprefrontal cortex injections (Aguiar *et al*, 2009; Micale *et al*, 2009; Rubino *et al*, 2008).

So far, most studies have investigated the roles of CB₁ and TRPV1 separately. However, there is evidence that they may act in concert to modulate behavioral responses (Maione *et al*, 2006; Micale *et al*, 2009; Rubino *et al*, 2008). They are co-expressed in several regions related to aversion, such as prefrontal cortex, amygdaloid complex and hippocampus, where they may modulate anxiety-related responses (Cristino *et al*, 2006; Micale *et al*, 2009), as well as in the ventrolateral PAG (vPAG), where they control nociceptive reactions (Cristino *et al*, 2006; Maione *et al*, 2006).

Considering this background, the present study tested the hypothesis that CB₁ and TRPV1 exert opposite effects on panic-like responses at level of the dPAG and looked for interdependences of the two signaling systems.

MATERIALS AND METHODS

Animals

Male Wistar rats were obtained from the animal facilities at the University of São Paulo, Ribeirão Preto. The animals, weighing 300–330 g, were housed in groups of 4–6 per cage under a 12-h dark/12-h light cycle (lights on at 0700 h) at 22 ± 1 °C, and given free access to food and water. All experiments were carried in accordance with the Brazilian Society of Neuroscience and Behavior for the care and use of laboratory animals and were approved by the

Experimental Animal Ethical Committee of University of São Paulo (protocol number: 114/2007). All efforts were made to minimize animal suffering.

Surgery

Rats were anesthetized with 2,2,2 tribromoethanol (250 mg/kg i.p.) combined with local anesthesia (2% lidocaine with a vasoconstrictor; Harvey, Brazil), and fixed in a stereotaxic frame (David Kopf) for implantation of a chemitrode in the dPAG (incisor bar 3.3 mm below the interaural line, 1.7 mm lateral to lambda at an angle of 22° with the sagittal plane, 5.0 mm below the surface of the skull; according to Paxinos and Watson, 1997). The chemitrode consisted of a stainless steel guide cannula (outer diameter: 0.6 mm, length: 13 mm) glued to a brain electrode made of stainless steel wire (diameter: 250 µm) that was insulated by enamel except for the cross-section of the tip. The electrode reached 1 mm below the end of the cannula. It was connected to a male pin parallel to the outer end of the cannula that could be plugged into an amphenol socket at the end of a flexible electrical cable. The chemitrode was fixed to the skull by means of acrylic resin and two stainless steel screws. A stylet was inserted into the guide cannula in order to prevent obstruction. At the end of the surgery, animals were treated with an antibiotic (Pentabiotico, Fort Dodge, Brazil; 1.0 ml/kg, i.m.) and flunixin meglumine (Schering-Plough, Brazil; 2.5 mg/kg, s.c.), which has analgesic, antipyretic and anti-inflammatory properties. The animals were left undisturbed for 5–7 days after the surgery.

Drugs and Treatment

The CB₁ agonist, arachidonyl-2-chloro-ethylamide (ACEA; Tocris) was dissolved in Tocrisolve (vehicle). The CB₁ antagonist, *N*-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazole-3-carboxamide (AM251; Tocris) and the TRPV1 antagonists, capsazepine (Tocris) and 4'-Chloro-3-methoxycinnamanilide (SB366791; Tocris), were dissolved in DMSO.

For local drug treatment, an injection needle (outer diameter: 0.3 mm) was inserted through the guide into the dPAG to a final depth of 6.0 mm below the surface of the skull. A volume of 0.2 µl was injected for 60 s using a 10-µl microsyringe (Hamilton) attached to a microinfusion pump (KD Scientific). The needle was left in place for another 60 s before removal.

Escape Threshold Determination

Escape behavior induced by dPAG electrical stimulation was performed in accordance with previous work (Casarotto *et al*, 2010). The animals were evaluated in a circular arena (40 cm in diameter) with 40 cm high walls made of transparent Plexiglas. Brain stimuli were generated by a sine-wave stimulator. The stimulation current (peak-to-peak) was monitored on the screen of an oscilloscope (Minipa, Brazil). The brain electrode was connected to the stimulator by means of an electromechanical swivel and a flexible cable, allowing ample movement of the animal inside the experimental cage. The escape threshold was determined in response to an electrical stimulus (AC, 60 Hz, 10 s)

presented through the chemitrode. The interstimulus interval was 10 s. The current intensity started at 20 μ A and was increased by steps of 4 μ A until the rat started running around the circular arena (escape behavior). In most cases, this vigorous reaction was accompanied by vertical jumps. When these behaviors were observed, electrical stimulation to the dPAG was interrupted by the experimenter that was blind to the treatment groups. The basal escape threshold was defined as the lowest current intensity that evoked escape in three successive trials of electrical stimulation. Animals with basal thresholds > 150 μ A were excluded from the study. Following basal escape threshold determination, independent groups of animals were injected with the drugs or vehicle into the dPAG, and the escape threshold was re-analyzed 10 min later. The variation in escape threshold (Δ) was then calculated for each animal and refers to the difference between escape threshold values obtained post- and pre-treatment.

Experiments

Independent batches of animals were used in each experiment. In experiment 1, the rats were treated with ACEA (0.01, 0.05 and 0.5 pmol) or vehicle ($n=6-7$). In experiment 2, new groups of animals received AM251 (75 pmol) or its vehicle followed by ACEA (0.05 pmol) or its respective vehicle 5 min later ($n=5-6$). In experiment 3, they were injected with capsaizipine (0.1, 1 and 10 nmol) or vehicle ($n=6-9$). In experiment 4, capsaizipine (0.1 nmol) or vehicle injections were followed by ACEA (0.5 pmol) 5 min later ($n=5$ per group). In experiment 5, the rats were treated with AM251 (75 pmol) or vehicle followed by capsaizipine (10 nmol) or vehicle 5 min later ($n=5-7$). Finally, in experiment 6, they were treated with AM251 (75 pmol) or vehicle followed by SB366791 (10 nmol) or vehicle 5 min later ($n=5-7$). The doses of ACEA, AM 251 and capsaizipine were selected based on previous works performing injections into the dPAG (Moreira *et al*, 2007; Terzian *et al*, 2009). The dose of SB366791 was selected based on the affinity of this substance for TRPV1 as compared with other antagonists (Gawa *et al*, 2005; Gunthorpe *et al*, 2004).

Histology

After the experiments, animals were deeply anesthetized with chloral hydrate. The brain was perfused through the heart with saline solution followed by 10% formalin solution, before being removed and fixed in 10% formalin. Frozen sections of 55 μ m were cut using a microtome to localize the positions of the electrode tips according to the atlas by Paxinos and Watson (1997). Only data from rats having chemitrode tips inside the dPAG were included in the statistical analysis.

Immunofluorescence

Male Wistar rats were anaesthetized with urethane and transcardially perfused with saline followed by 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (PBS, pH 7.4). The brain was removed and post-fixed over 2 h in PFA 4% and stored for at least 30 h in 30% sucrose for

cryoprotection. Coronal sections (25 μ m) were obtained in a cryostat and were washed in PBS 0.01 M. After this, the sections were incubated in glycine 0.1 M, washed again and incubated for 1 h in 5% bovine serum (BSA, sigma) in PBS 0.01 M, pH 7.4 containing 0.3% Triton X-100. Thereafter, the sections were incubated for 2 days at 4 °C in a mixture of anti-CB₁ receptor N-terminus (1:250; Abcam raised in rabbit) to anti-TRPV1 receptor N-terminus (1:100; Santa Cruz raised in goat) diluted in PBS 0.01 M containing BSA 5% and 0.3% Triton X-100. After incubation in the primary antiserum, the tissue sections were washed in PBS and sequentially incubated in a mixture of Alexa 594 donkey anti-rabbit IgGs (1:1000; Molecular Probes, Eugene, OR) and Alexa 488 donkey anti-goat IgGs (1:1000; Molecular Probes) for 1 h. Slides were rinsed in PBS and coverslipped with Fluormount-G (Electron Microscopy Sciences, Hatfield, PA). Images were first obtained using an Olympus BX50 microscope through computerized image system (Image Pro-Plus 4.0, Media Cybernetics). For a more appropriate analysis of double-stained cells, the slides were re-examined using a modified Olympus BX61WI confocal microscope in an upright configuration, using an Argonion laser at 488 nm. Immunostained slides (Alexa Fluor 488-coupled anti-CB₁ receptors; Alexa Fluor 546-coupled anti-TRPV1 receptors) were exposed for 2.71 s and green and red channels were merged digitally by Fluoview software. Images were further exported in TIFF format. The specificity of the primary antibodies has been demonstrated before by means of CB₁ and TRPV1 knockout mice (Maione *et al*, 2006). Nevertheless, we additionally performed negative controls for non-specific labeling. The protocol was the same as described above, except for the fact that the primary antibodies for CB₁ and TRPV1 were switched, so that each protocol would include a primary antibody for one receptor and a secondary for the other.

Statistical Analysis

The effects of intradPAG drug injections were analyzed by Student's *t*-test or by one-way analysis of variance (ANOVA) followed by Newman-Keuls *post hoc* test, when appropriate. Data were expressed as mean $\pm$ SEM. Statistical significance was accepted if $p < 0.05$.

RESULTS

The sites of electrical stimulation and drug injection can be seen in Figure 1. Electrical stimulation of the dPAG (black dots), but not of surrounding regions (gray dots), caused an explosive panic response, which was characterized by running and jumping. Activation of CB₁ receptors by local administration of ACEA modified the effects of electrical stimulation in a bell-shaped manner. It increased the threshold for inducing escape behavior at 0.05 pmol, though not at 0.01 or 0.5 pmol ($F(3,23) = 4.06$; $p < 0.05$; Figure 2). The panicolytic-like effect of 0.05 nmol ACEA was mediated by CB₁ receptors, since it could be blocked by pre-treatment with the selective antagonist AM251 (75 pmol) ($F(3,17) = 13.86$; $p < 0.01$; Figure 3). Local blockade of TRPV1 channels by capsaizipine also raised the escape threshold at 1 and 10 nmol ($F(3,25) = 16.58$; $p < 0.05$; Figure 4).

Figure 1 Schematic representation of coronal sections from interaural line of the rat brain (Paxinos and Watson, 1997) showing the injection/electrical stimulation sites inside (dark circles) of the dPAG. Sites where electrical stimulation failed to induce escape responses are also presented (gray circles). Due to overlaps, the number of points represented is fewer than the number of rats actually employed in the experiments.

Figure 2 Local injection of the selective CB₁-receptor agonist, ACEA, into the dPAG increases the threshold of electric current necessary for inducing panic-like response ($n=7, 6, 7, 7$). Following basal escape threshold determination, independent groups of animals were injected with vehicle or ACEA (0.01–0.5 pmol), and the escape threshold was re-analyzed 10 min later. The variation in escape threshold (Δ) was then calculated for each animal and refers to the difference between escape threshold values obtained post- and pre-treatment. * $p<0.05$ Compared with all other groups (one-way ANOVA followed by Newman-Keuls *post hoc* test).

These results suggest that TRPV1 has diametrically opposite functions as compared with CB₁. Considering that certain cannabinoids may also bind TRPV1 at higher concentrations (Huang *et al*, 2002; Price *et al*, 2004; Silveira

Figure 3 Local pre-treatment (5 min) with the CB₁ antagonist, AM251 (75 pmol), prevents ACEA (0.05 pmol)-induced panicolytic-like effect ($n=5, 6, 5, 5$). * $p<0.05$ Compared with all other groups (one-way ANOVA followed by Newman-Keuls *post hoc* test). For further details, see legend to Figure 2.

Figure 4 Local injection of the TRPV1 antagonist, capsazepine (CPZ; 0.1–10 nmol), into the dPAG increases the threshold of electric current required for inducing panic-like response ($n=9, 7, 6, 7, 7$). * $p<0.05$ Compared with vehicle-treated rats (one-way ANOVA followed by Newman-Keuls *post hoc* test). For further details, see legend to Figure 2.

et al, 2010; Smart *et al*, 2000; Zygmunt *et al*, 1999), simultaneous CB₁ and TRPV1 activation could explain the bell-shaped effects observed with ACEA in the first experiment (Figure 2). High-dose ACEA could activate both CB₁ and TRPV1, occluding the CB₁-mediated effects. Indeed, an ineffective dose of capsazepine (0.1 nmol) unmasked the panicolytic-like effect of ACEA (0.5 pmol) ($t(8)=3.48$; $p<0.01$; Figure 5).

Finally, we tested the hypothesis that the panicolytic-like effect of TRPV1 blockade would occur because it would shift the action of a common endogenous agonist toward CB₁ activation. Supporting this hypothesis, the panicolytic-like effect of capsazepine at higher doses (10 nmol) could be

Figure 5 Local pre-treatment (5 min) with the TRPV1 antagonist, capsazepine (CPZ; 0.1 nmol), unmasks the panicolytic-like effect of high-dose ACEA (0.5 pmol) ($n=5$ per group). * $p<0.05$ Compared with all other groups (one-way ANOVA followed by Newman-Keuls *post hoc* test). For further details, see legend to Figure 2.

Figure 6 Local pre-treatment (5 min) with the CB₁ antagonist, AM251 (75 pmol), prevents the panicolytic-like effect of capsazepine (CPZ; 10 nmol)-induced ($n=5, 7, 5, 7$). * $p<0.05$ Compared with all other groups (one-way ANOVA followed by Newman-Keuls *post hoc* test). For further details, see legend to Figure 2.

prevented by pre-treatment with AM251 (75 pmol), demonstrating its dependency on CB₁ signaling ($F(3,20)=5.74$; $p<0.01$; Figure 6). Remarkably, this data could be reproduced with a more selective TRPV1 antagonist, SB366791 (10 nmol), which increased the threshold for

Figure 7 Local pre-treatment (5 min) with the CB₁ antagonist, AM251 (75 pmol), prevents the panicolytic-like effect of SB366791 (10 nmol) ($n=6, 6, 5, 7$). * $p<0.05$ Compared with all other groups (one-way ANOVA followed by Newman-Keuls *post hoc* test). For further details, see legend to Figure 2.

panic-like responses to the same extent as capsazepine, again in a CB₁-dependent manner (75 nmol), as presented in Figure 7 ($F(3,20)=16.3$; $p<0.01$; Figure 7).

At the cellular level, both CB₁ and TRPV1 are expressed in neurons within the dPAG (Figure 8). Immunofluorescent labeling revealed neurons that were exclusively CB₁ or TRPV1 positive. However, many neurons co-expressed both receptors in their cell bodies. This could be certified through confocal microscopy examination, which allowed us to distinguish double-stained neurons from pairs of mono-stained neurons located in adjacent plans. There was a medium degree of colocalization throughout the dorso-lateral and dorsomedial aspects of the PAG. This pattern of co-expression supports the notion that they could be simultaneously activated at a given synapse. Importantly, no staining was observed in protocols in which the antibodies were switched, so that the primary for one receptor was combined with the secondary for the other (Figure 9). This re-assures the specificity of the antibodies used in the present protocols.

DISCUSSION

The present work provides evidence for opposite functions of CB₁ and TRPV1 in an animal model of panic attacks, the electrical stimulation of the dPAG. In this model, local application of antipanic drugs increases the current threshold necessary for the induction of explosive escape behaviors. We demonstrated that the selective CB₁ agonist, ACEA, increased the threshold for inducing panic-like reaction in a bell-shaped manner. This panicolytic-like effect was completely prevented by the CB₁ receptor antagonist, AM251. Although this effect was lost in a higher dose, it could be unmasked by previous treatment with an inactive dose of capsazepine, a TRPV1 antagonist. In addition, pharmacological blockade of TRPV1 *per se* also exerted panicolytic-like effects, suggesting the existence of

Figure 8 CB₁ receptors and TRPV1 channels are co-expressed in neurons in the dPAG. The photomicrographs (25 μm thick section) show image of double-label immunofluorescence of CB₁ (red, Alexa Fluor 594; a, d) and TRPV1 receptors (green, Alexa Fluor 488; b, e), as revealed by fluorescence (a–c) and confocal (d–f) microscopy. Panel (c) (the composite images of (a, b)) shows neurons expressing both receptors. One representative double-stained neuron is shown in higher magnification in f (arrow). Scale bars: 100 μm (a–c) and 50 μm (d–f).

Figure 9 Negative controls for the double-labeled immunofluorescence. The photomicrographs (25 μm thick section) show images of the dPAG from protocols combining TRPV1 secondary (Alexa Fluor 488) with CB₁ primary antibodies (a) or CB₁ secondary (Alexa Fluor 594) with TRPV1 primary antibodies (b). Images resulting from protocol in which the primary antibodies were omitted as seen in the microscopy through filters for Alexa Fluor 488 (c) and Alexa Fluor 594 (d) are also shown.

tonic modulation by TRPV1, whose function opposed that of CB₁. Remarkably, capsazepine effect could be prevented by AM251, revealing that the effect of TRPV1 blockade was completely dependent on CB₁ signaling. Noteworthy, capsazepine effect could be mimicked by another TRPV1 antagonist, SB366791, whose action was also prevented by AM251. Together with the co-expression of CB₁ and TRPV1 observed at level of the dPAG, these data suggest the existence of a set-point system, whereby activation of TRPV1 vs CB₁ balances the induction of panic-like responses.

The dPAG model of panic has some limitations in terms of a broader interpretation in relationship to human psychopathology. It mimics only the panic attacks, which actually occur with several other symptoms of panic disorder, such as behavioral and physiological signs of intense anxiety, fear and distress (Katon, 2006; Roy-Byrne *et al*, 2006). Moreover, it is based on the measure of an all-or-none response to electrical stimulation of a specific brain structure, which is only part of a more complex neural circuitry generating fear, anxiety and panic responses (Del-Ben and Graeff, 2009). Despite of these drawbacks, this model presents face, construct and predictive validities (Jenck *et al*, 1995; Beckett and Marsden, 1995; Del-Ben and Graeff, 2009; Schenberg *et al*, 2001). The face validity is supported by the fact that the behavioral and autonomic responses observed in this model resemble those seen in panic attacks (Schenberg *et al*, 2001). As for the theoretical construct, the PAG is a midbrain structure activated during escape responses induced by natural aversive stimulus either in laboratory animals or in healthy volunteers (Dielenberg *et al*, 2001; Mobbs *et al*, 2007). Neurosurgery patients, in whom this structure has been electrically stimulated, reported feelings of fear and despair similar to those described in panic patients (Nashold *et al*, 1969). Finally, and more relevant for the present study, the pharmacological predictability of the model is supported by the observations that drugs used to treat panic disorder increase the threshold of escape responses induced by electrical stimulation of the dPAG (Jenck *et al*, 1995; Schenberg *et al*, 2001; Schütz *et al*, 1985).

In this model, ACEA induced a panicolytic-like effect in an intermediary dose, which could be prevented by AM251, in line with previous experiments in anxiety-related reactions (Moreira *et al*, 2007). These results support the concept of general anti-aversive effects of CB₁ signaling at level of the PAG. Accordingly, local injections of other cannabinoids inhibit the escape responses induced by local injection of an excitatory amino acid (Finn *et al*, 2003) and

promote anxiolytic-like effects in several animal models (for a review, see Moreira *et al*, 2009).

Contrary to CB₁, TRPV1 seems to mediate pro-aversive effects, since we detected a clear panicolytic-like effect after its blockade with capsazepine or SB366791. Moreover, an ineffective dose of capsazepine was able to unmask the panicolytic-like effects of higher dose of ACEA. Therefore, the bell-shaped dose-response curve of ACEA seems to result from an activation of CB₁ at lower concentrations (panicolytic), whereas higher concentration of ACEA also activates the less affine TRPV1 channels (panicogenic), counteracting CB₁-mediated actions, resulting in a net null effect. This is in line with ACEA affinities profile, binding CB₁ in lower dose (Gawa *et al*, 2005) and both CB₁ and TRPV1 in higher dose (Huang *et al*, 2002; Price *et al*, 2004; Silveira *et al*, 2010; Smart *et al*, 2000; Zygmunt *et al*, 1999).

The panicolytic consequences of TRPV1 antagonists speak for a tonic activation of TRPV1 under basal conditions. This is in accordance with previous studies, which reported decreased anxiety upon pharmacological or genetic interruption of TRPV1 signaling. For instance, systemic injection of capsazepine reduced anxiety-like behavior in rats (Kasckow *et al*, 2004). Moreover, a detailed investigation on the behavior of TRPV1 knockout mice unveiled a phenotype of reduced anxiety-like behavior in the elevated plus maze and in the light-dark box, as well as reduced fear conditioning (Marsch *et al*, 2007). In addition, the effect of systemically administered capsazepine is mimicked by local injection into specific structures, namely the ventral hippocampus (Santos *et al*, 2008), the dorso-lateral PAG (Terzian *et al*, 2009) and the prefrontal cortex (Aguir *et al*, 2009; Rubino *et al*, 2008). This is consonant with neurochemical and electrophysiological data showing that this ion channel stimulates calcium influx and glutamate release in the PAG, increasing local neuronal activity (Starowicz *et al*, 2007b; Xing and Li, 2007). In addition, it has been demonstrated in other brain regions related to anxiety and emotional processing, such as the hippocampus and the nucleus accumbens, that anandamide acts upon TRPV1 modulates long-termed depression of synaptic activity (Chavez *et al*, 2010; Grueter *et al*, 2010). Although it remains unclear how these electrophysiological events would reflect behavioral responses, these studies suggest that anandamide could be the endogenous substance activating this ion channel (Di Marzo, 2010; Chavez *et al*, 2010; Grueter *et al*, 2010). Other lipids, including *N*-arachidonoyl dopamine, *N*-oleoyldopamine and some lipoxygenase products have also been among the main candidates proposed as endovanilloids (Di Marzo *et al*, 2001; Starowicz *et al*, 2007a).

Remarkably, the effects of TRPV1 blockade could be fully prevented by pre-treatment with the selective CB₁ antagonist, AM251. Thus, we have shown that the effect of TRPV1 antagonists is ultimately mediated by CB₁ receptor, possibly because the actions of an endogenous agonist would be entirely shifted to CB₁, after TRPV1 blockade. This finding adds to previous observations about opposite roles for CB₁ and TRPV1 in various behavioral responses (Maione *et al*, 2006; Micale *et al*, 2009; Rubino *et al*, 2008). We suggest that CB₁ and TRPV1 might be simultaneously activated at a given synapse, since we observed co-expression of CB₁ and TRPV1 at level of the dPAG. Similar observations were

obtained before in the prefrontal cortex, amygdala complex, hippocampus and vPAG (Cristino *et al*, 2006; Maione *et al*, 2006; Micale *et al*, 2009). In accordance with previous studies, we also detected dPAG neurons that were either exclusively CB₁ positive (Herkenham *et al*, 1990, 1991; Tsou *et al*, 1998) or TRPV1 positive (McGaraughty *et al*, 2003; Mezey *et al*, 2000; Tóth *et al*, 2005).

Our pharmacological and histological experiments support a scenario in which TRPV1 and CB₁ would counteract each other to balance the threshold for panic-like responses in multiple ways. For instance, the opposite effects of CB₁ and TRPV1 could be mediated by different neurons that converge on the same output system. Alternatively, they could result from divergent influences on intracellular signaling, neural firing rates and neurotransmitter release within the same neurons (Kawahara *et al*, 2010; Starowicz *et al*, 2007b; Vaughan *et al*, 2000; Xing and Li, 2007). Regarding the physiological modulation of these mechanisms, there might be an endogenous agonist, with affinity for both, which would be part of a tripartite system to establish set points for behavioral responses. One candidate would be anandamide, which has been proposed as an endocannabinoid/endovanilloid (Zygmunt *et al*, 2000), with higher affinity for CB₁ as compare with TRPV1 (Di Marzo *et al*, 2001; Starowicz *et al*, 2007a).

Despite of the facts that anandamide has lower affinity for TRPV1 and has its actions limited by the enzyme fatty acid amide hydrolase (FAAH; Piomelli, 2003), the local levels of this substance are significantly increased by electrical stimulation of the dPAG (Walker *et al*, 1999). Therefore, it is conceivable that, in the present model, anandamide levels would increase and act upon both receptors, whereby TRPV1-mediated actions may prevail over CB₁ (Tognetto *et al*, 2001), thus facilitating panic-like behavior. Blockade of this ion channel would increase the threshold by shifting anandamide action entirely to CB₁ receptors, whose selective activation is panicolytic. This hypothesis is reinforced by recent electrophysiological and behavioral experiments. In PAG slices, anandamide could either facilitate or inhibit excitatory transmission through TRPV1 and CB₁, respectively, in the presence of the hydrolysis inhibitor URB597 (Kawahara *et al*, 2010). Accordingly, FAAH knockout mice have a phenotype of lower anxiety-like behavior due to higher CB₁ activation by anandamide. However, CB₁-antagonist treatment induced anxiogenic-like effects in these animals, but not in wild-type controls, possibly by shifting anandamide activity toward TRPV1 (Cassano *et al*, 2010).

In conclusion, we have shown opposite functions for TRPV1 and CB₁ receptors in the modulation of panic-like responses at the level of the dPAG. Anandamide actions via CB₁ vs TRPV1 may constitute a set-point system that represents a promising target for the pharmacotherapy of panic and other anxiety spectrum disorders.

ACKNOWLEDGEMENTS

We thank Dr Vincenzo, Di Marzo and Dr Luigia Cristino (Endocannabinoid Research Group, Italy) for the helpful insights with the immunofluorescence. We also thank Dr Gustavo Menezes and Dr Ana Maria de Paulo (Federal

University of Minas Gerais) for the assistance with confocal microscopy. Finally, we thank Eleni T Gomes, José C de Aguiar and Afonso Padovan (University of São Paulo) for the technical assistance. ALT is a recipient of a CNPq/DAAD fellowship (290008/2009-3). FAM thanks FAPEMIG for the research grant APQ-01446-09. DCA thanks FAPEMIG for the research grant APQ-01883-09.

DISCLOSURE

The authors declare no conflict of interest.

REFERENCES

- Aguiar DC, Terzian AL, Guimarães FS, Moreira FA (2009). Anxiolytic-like effects induced by blockade of transient receptor potential vanilloid type 1 (TRPV1) channels in the medial prefrontal cortex of rats. *Psychopharmacology (Berl)* 205: 217–225.
- Bandler R, Keay KA, Floyd N, Price J (2000). Central circuits mediating patterned autonomic activity during active vs. passive emotional coping. *Brain Res Bull* 53: 95–104.
- Beckett S, Marsden CA (1995). Computer analysis and quantification of periaqueductal grey-induced defense behaviour. *J Neurosci Methods* 58: 157–161.
- Casarotto PC, de Bortoli VC, Corrêa FM, Resstel LB, Zangrossi Jr H (2010). Panicolytic-like effect of BDNF in the rat dorsal periaqueductal grey matter: the role of 5-HT and GABA. *Int J Neuropsychopharmacol* 13: 573–582.
- Cassano T, Gaetani S, Macheda T, Laconca L, Romano A, Morgese MG et al (2010). Evaluation of the emotional phenotype and serotonergic neurotransmission of fatty acid amide hydrolase-deficient mice. *Psychopharmacology (Berl)*, print copy in press (originally published online 2 November 2010 at <http://www.springerlink.com/content/r6351r2q7t881t25/fulltext.pdf>).
- Cavanaugh DJ, Chesler AT, Jackson AC, Sigal YM, Yamanaka H, Grant R et al (2011). Trpv1 reporter mice reveal highly restricted brain distribution and functional expression in arteriolar smooth muscle cells. *J Neurosci* 31: 5067–5077.
- Chavez AE, Chiu CQ, Castillo P (2010). TRPV1 activation by endogenous anandamide triggers post synaptic long-term depression in dentate gyrus. *Nat Neurosci* 13: 1511–1519.
- Cristino L, de Petrocellis L, Pryce G, Baker D, Guglielmotti V, Di Marzo V (2006). Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. *Neuroscience* 139: 1405–1415.
- Del-Ben CM, Graeff FG (2009). Panic disorder: is the PAG involved? *Neural Plast* 2009: 108135.
- Di Marzo V (2008). Targeting the endocannabinoid system: to enhance or reduce? *Nat Rev Drug Discov* 7: 438–455.
- Di Marzo V (2010). Anandamide server two masters in the brain. *Nat Neurosci* 13: 1446–1448.
- Di Marzo V, Bisogno T, De Petrocellis L (2001). Anandamide: some like it hot. *Trends Pharmacol Sci* 22: 346–349.
- Dielenberg RA, Hunt GE, McGregor IS (2001). 'When a rat smells a cat': the distribution of Fos immunoreactivity in rat brain following exposure to a predatory odor. *Neuroscience* 104: 1085–1097.
- Finn DP, Jhaveri MD, Beckett SR, Roe CH, Kendall DA, Marsden CA et al (2003). Effects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in rats. *Neuropharmacology* 45: 594–604.
- Gawa NR, Tamir R, Klionsky L, Norman MH, Louis JC, Wild KD et al (2005). Proton activation does not alter antagonist interaction with the capsaicin-binding pocket of TRPV1. *Mol Pharmacol* 68: 1524–1533.
- Grueter BA, Brasnjo G, Malenka RC (2010). Post synaptic TRPV1 triggers cell-type specific long-term depression in the nucleus accumbens. *Nat Neurosci* 13: 1519–1526.
- Gunthorpe MJ, Rami HK, Jerman JC, Smart D, Gill CH, Soffin EM et al (2004). Identification and characterization of SB-366791, a potent and selective vanilloid receptor (VR1/TRPV1) antagonist. *Neuropharmacology* 46: 133–149.
- Haller J, Bakos N, Szirmay M, Ledent C, Freund TF (2002). The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. *Eur J Neurosci* 16: 1395–1398.
- Haller J, Varga B, Ledent C, Freund TF (2004). CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. *Behav Pharmacol* 15: 299–304.
- Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991). Characterization and localization of cannabinoid receptors in rat brain: a quantitative *in vitro* autoradiographic study. *J Neurosci* 11: 563–583.
- Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR et al (1990). Cannabinoid receptor localization in brain. *Proc Natl Acad Sci USA* 87: 1932–1936.
- Hogg S, Michan L, Jessa M (2006). Prediction of anti-panic properties of escitalopram in the dorsal periaqueductal grey model of panic anxiety. *Neuropharmacology* 51: 141–145.
- Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F et al (2002). An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. *Proc Natl Acad Sci USA* 99: 8400–8405.
- Jacob W, Yassouridis A, Marsicano G, Monory K, Lutz B, Wotjak CT (2009). Endocannabinoids render exploratory behaviour largely independent of the test aversiveness: role of glutamatergic transmission. *Genes Brain Behav* 8: 685–698.
- Jenck F, Moreau JL, Martin JR (1995). Dorsal periaqueductal gray-induced aversion as a simulation of panic anxiety: elements of face and predictive validity. *Psychiatry Res* 57: 181–191.
- Kamprath K, Marsicano G, Tang J, Monory K, Bisogno T, Di Marzo V et al (2006). Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes. *J Neurosci* 26: 6677–6686.
- Kasckow JW, Mulchahey JJ, Geraciotti Jr TD (2004). Effects of the vanilloid agonist olvanil and antagonist capsazepine on rat behaviors. *Prog Neuropsychopharmacol Biol Psychiatry* 28: 291–295.
- Katon WJ (2006). Clinical practice. Panic disorder. *N Engl J Med* 354: 2360–2367.
- Kawahara H, Drew GM, Christie MJ, Vaughan CW (2010). Inhibition of fatty acid amide hydrolase unmasks CB(1) receptor and TRPV1 channel-mediated modulation of glutamatergic synaptic transmission in midbrain periaqueductal grey. *Br J Pharmacol*, print copy in press (originally published online 22 December 2010 at <http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2010.01157.x/pdf>).
- Krieger JE, Graeff FG (1985). Defensive behavior and hypertension induced by glutamate in the midbrain central gray of the rat. *Braz J Med Biol Res* 18: 61–67.
- Lisboa SF, Resstel LB, Aguiar DC, Guimarães FS (2008). Activation of cannabinoid CB1 receptors in the dorsolateral periaqueductal gray induces anxiolytic effects in rats submitted to the Vogel conflict test. *Eur J Pharmacol* 593: 73–78.
- Maione S, Bisogno T, de Novellis V, Palazzo E, Cristino L, Valenti M et al (2006). Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor

- potential vanilloid type-1 receptors. *J Pharmacol Exp Ther* **316**: 969–982.
- Marsch R, Foeller E, Rammes G, Bunck M, Kössl M, Holsboer F et al (2007). Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice. *J Neurosci* **27**: 832–939.
- Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG et al (2002). The endogenous cannabinoid system controls extinction of aversive memories. *Nature* **418**: 530–534.
- Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O (2002). Involvement of CB₁ cannabinoid receptors in emotional behaviour. *Psychopharmacology (Berl)* **159**: 379–387.
- McGaraughy S, Chu KL, Bitner RS, Martino B, El Kouhen R, Han P et al (2003). Capsaicin infused into the PAG affects rat tail flick responses to noxious heat and alters neuronal firing in the RVM. *J Neurophysiol* **90**: 2702–2710.
- McNaughton N, Gray JA (2000). Anxiolytic action on the behavioural inhibition system implies multiple types of arousal contribute to anxiety. *J Affect Disord* **61**: 161–176.
- Mezey E, Tóth ZE, Cortright DN, Arzubi MK, Krause JE, Elde R et al (2000). Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. *Proc Natl Acad Sci USA* **97**: 3655–3660.
- Micale V, Cristino L, Tamburella A, Petrosino S, Leggio GM, Drago F et al (2009). Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. *Neuropsychopharmacology* **34**: 593–606.
- Mobbs D, Petrovic P, Marchant JL, Hassabis D, Weiskopf N, Seymour B et al (2007). When fear is near: threat imminence elicits prefrontal-periaqueductal gray shifts in humans. *Science* **317**: 1079–1083.
- Moreira FA, Aguiar DC, Campos AC, Lisboa SF, Terzian AL, Resstel LB et al (2009). Antiaversive effects of cannabinoids: is the periaqueductal gray involved? *Neural Plast* **2009**: 625469.
- Moreira FA, Aguiar DC, Guimarães FS (2007). Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray. *Neuropharmacology* **52**: 958–965.
- Nashold Jr BS, Wilson WP, Slaughter DG (1969). Sensations evoked by stimulation in the midbrain of man. *J Neurosurg* **30**: 14–24.
- Paxinos G, Watson C (1997). *The Rat Brain in Stereotaxic Coordinates*. 3rd edn. Academic Press: San Diego.
- Piomelli D (2003). The molecular logic of endocannabinoid signalling. *Nat Rev Neurosci* **4**: 873–884.
- Price TJ, Patwardhan A, Akopian AN, Hargreaves KM, Flores CM (2004). Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonoyl-2-chloroethylamide. *Br J Pharmacol* **141**: 1118–1130.
- Roy-Byrne PP, Craske MG, Stein MB (2006). Panic disorder. *Lancet* **368**: 1023–1032.
- Rubino T, Realini N, Castiglioni C, Guidali C, Viganó D, Marras E et al (2008). Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. *Cereb Cortex* **18**: 1292–1301.
- Santos CJ, Stern CA, Bertoglio LJ (2008). Attenuation of anxiety-related behaviour after the antagonism of transient receptor potential vanilloid type 1 channels in the rat ventral hippocampus. *Behav Pharmacol* **19**: 357–360.
- Schenberg LC, Bittencourt AS, Sudré EC, Vargas LC (2001). Modeling panic attacks. *Neurosci Biobehav Rev* **25**: 647–659.
- Schütz MT, de Aguiar JC, Graeff FG (1985). Anti-aversive role of serotonin in the dorsal periaqueductal grey matter. *Psychopharmacology (Berl)* **85**: 340–345.
- Silveira PE, Silveira NA, Morini Vde C, Kushmerick C, Naves LA (2010). Opposing effects of cannabinoids and vanilloids on evoked quantal release at the frog neuromuscular junction. *Neurosci Lett* **473**: 97–101.
- Smart D, Gunthorpe MJ, Jerman JC, Nasir S, Gray J, Muir AI (2000). The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). *Br J Pharmacol* **129**: 227–230.
- Starowicz K, Maione S, Cristino L, Palazzo E, Marabese I, Rossi F et al (2007b). Tonic endovanilloid facilitation of glutamate release in brainstem descending antinociceptive pathways. *J Neurosci* **27**: 13739–13749.
- Starowicz K, Nigam S, Di Marzo V (2007a). Biochemistry and pharmacology of endovanilloids. *Pharmacol Ther* **114**: 13–33.
- Terzian AL, Aguiar DC, Guimarães FS, Moreira FA (2009). Modulation of anxiety-like behaviour by Transient Receptor Potential Vanilloid Type 1 (TRPV1) channels located in the dorsolateral periaqueductal gray. *Eur Neuropsychopharmacol* **19**: 188–195.
- Tognetto M, Amadesi S, Harrison S, Creminon C, Trevisani M, Carreras M et al (2001). Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation. *J Neurosci* **21**: 1104–1109.
- Tóth A, Boczán J, Kedei N, Lizanecz E, Bagi Z, Papp Z et al (2005). Expression and distribution of vanilloid receptor 1 (TRPV1) in the adult rat brain. *Brain Res Mol Brain Res* **135**: 162–168.
- Tsou K, Brown S, Sañudo-Peña MC, Mackie K, Walker JM (1998). Immunohistochemical distribution of cannabinoid CB₁ receptors in the rat central nervous system. *Neuroscience* **83**: 393–411.
- Vaughan CW, Connor M, Bagley EE, Christie MJ (2000). Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons *in vitro*. *Mol Pharmacol* **57**: 288–295.
- Walker JM, Huang SM, Strangman NM, Tsou K, Sañudo-Peña MC (1999). Pain modulation by release of the endogenous cannabinoid anandamide. *Proc Natl Acad Sci USA* **96**: 12198–12203.
- Xing J, Li J (2007). TRPV1 receptor mediates glutamatergic synaptic input to dorsolateral periaqueductal gray (dl-PAG) neurons. *J Neurophysiol* **97**: 503–511.
- Zygmunt PM, Julius D, Di Marzo V, Hogestatt ED (2000). Anandamide—the other side of the coin. *Trends Pharmacol Sci* **21**: 43–44.
- Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V et al (1999). Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. *Nature* **400**: 452–457.